StockData
Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc. (ATRA) stock

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$6.50+0.10 (+1.56%)

Close on Nov 17, 2026Market cap $65.25MP/E –Yield –

Atara Biotherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Atara Biotherapeutics's revenue for the twelve months ending Jun 30, 2026 was $6.19M, down 96.7% year over year. For fiscal 2025 it was $120.77M, down 6.3% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$120.77M-6.3%
FY2024Dec 31, 2024$128.94M+1404.0%
FY2023Dec 31, 2023$8.57M-86.5%
FY2022Dec 31, 2022$63.57M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$630.00K-96.4%
Q1 FY2026Mar 31, 2026$516.00K-99.5%
Q4 FY2025Dec 31, 2025$1.60M-95.1%
Q3 FY2025Sep 30, 2025$3.45M-91.4%
Q2 FY2025Jun 30, 2025$17.58M-38.6%
Q1 FY2025Mar 31, 2025$98.15M+258.8%
Q4 FY2024Dec 31, 2024$32.75M+670.3%
Q3 FY2024Sep 30, 2024$40.19M+1779.8%
Q2 FY2024Jun 30, 2024$28.64M+2892.7%
Q1 FY2024Mar 31, 2024$27.36M+2131.4%
Q4 FY2023Dec 31, 2023$4.25M+1824.0%
Q3 FY2023Sep 30, 2023$2.14M-52.1%
Q2 FY2023Jun 30, 2023$957.00K-98.1%
Q1 FY2023Mar 31, 2023$1.23M-83.2%
Q4 FY2022Dec 31, 2022$221.00K–
Q3 FY2022Sep 30, 2022$4.46M–
Q2 FY2022Jun 30, 2022$51.58M–
Q1 FY2022Mar 31, 2022$7.31M–

More Atara Biotherapeutics figures

See a number that looks wrong?